Handelsavisen
prelaunch
Companies ›Healthcare ›BUX.CD
BU
BUX.CD — — Biotechnology & Medical Research

BioMark Diagnostics Inc

$0,58
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-1 249,0 %
ROE
64,2 %
Net margin
-982,9 %
Debt / equity
-1,32
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

BioMark Diagnostics Inc is a biotechnology company focused on the development and commercialization of diagnostic solutions for infectious diseases and chronic conditions, primarily generating revenue through product sales and research collaborations.

Business. BioMark Diagnostics Inc (BUX.CD) is a biotechnology and medical research company operating within the healthcare sector. The firm focuses on pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not provided in the available data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
64,2 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BUX.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BUX.CD. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    BioMark Diagnostics Inc (BUX.CD) is a biotechnology and medical research company operating within the healthcare sector. The firm focuses on pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not provided in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    BioMark Diagnostics Inc has a negative equity position of CAD -609,610,000 and a debt-to-equity ratio of -1.32, indicating a leveraged capital structure with liabilities exceeding assets. The company's liquidity position is weak, with a current ratio of 0.16 and negative free cash flow of CAD -291,690,000, suggesting limited ability to meet short-term obligations without external financing.

    Profitability metrics are highly negative, with a net loss of CAD -391,310,000 and an operating loss of CAD -497,240,000. Return on equity is 64.19%, but this is misleading due to the negative equity base. Return on assets is -35.94%, significantly below the industry median for biotechnology firms, indicating poor asset utilization and operational efficiency.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits growth opportunities.

    Growth trajectory is negative, with no disclosed revenue growth in the current fiscal year. The company has not provided forward-looking guidance, and historical revenue trends show no signs of improvement. Capital expenditures are minimal at CAD -4,390,000, suggesting limited investment in future capacity or innovation.

    Risk factors include high liquidity risk due to negative free cash flow and a debt load exceeding cash reserves. The company has a low dilution risk, with no recent share issuance or shelf registration activity. However, the negative equity position and high debt-to-equity ratio suggest potential for future dilution if the company requires additional capital.

    Recent filings and transcripts indicate ongoing challenges in achieving profitability and securing additional financing. The company has not disclosed any material events or strategic shifts in the latest 10-K or earnings call transcripts.

    Key takeaways
    • BioMark Diagnostics Inc is operating at a significant net loss with negative equity, indicating financial distress.
    • The company's liquidity position is weak, with a current ratio of 0.16 and negative free cash flow.
    • Return on assets is -35.94%, significantly below industry norms, highlighting poor asset utilization.
    • Revenue is concentrated in a single segment with no geographic diversification, increasing market risk.
    • The company has not demonstrated growth in revenue or profitability, with no forward guidance provided.
    • Liquidity risk is high, and the company may require additional financing to continue operations.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    BioMark's ROE of 0.64 ranks in the best-in-class quartile, significantly outperforming the cohort median of -0.17.

    The company's debt-to-equity ratio of -1.32 is best-in-class compared to the cohort median of 0.02.

    Cash conversion of 2.51 is best-in-class, substantially exceeding the cohort median of 0.87.

    Dilution risk is assessed as low, suggesting limited immediate pressure on shareholder equity from share issuance.

    Long-term debt decreased to CAD 454,160 in FY0, down from CAD 805,940 in FY-1.

    BEAR CASE · 2

    Operating margin of -12.49% places BioMark in the bottom quartile, far worse than the cohort median of -1.98%.

    Credit risk is flagged as high, indicating significant potential for financial distress or default.

    In focus — financials by report

    Valuation FY

    Market price
    $0,58
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    -$609.6k
    Net cashⓘ
    -$649.2k
    Current ratioⓘ
    0.2
    Debt / equityⓘ
    -1.3
    ROAⓘ
    -35.9%
    ROEⓘ
    64.2%
    Cash conversionⓘ
    251.0%
    CapEx / revenueⓘ
    -11.0%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-1 249,0 %Bottom quartile
    Net Margin-982,9 %Below median
    ROE64,2 %Best in class
    Capex / Rev-11,0 %Below median
    D/E-1,32Best in class
    Cash Conv2,51Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • BioMark Diagnostics Inc Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BUX.CDCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage